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Fibrosis, which progressively deteriorates tissue function and eventually organ failure in 
various organs (lung, kidney, liver and skin), contributes to around 45% of deaths in the 
western world [1]. Although the liver has a high capacity for reversing chronic injury, persistent 
injury can develop to liver fibrosis and further to cirrhosis or even hepatocellular carcinoma 
(HCC), leading to liver failure, to which currently only liver transplantation is an effective 
therapy. Although it has long been thought that liver cirrhosis is not reversible, recent antiviral 
(hepatitis C and B) treatment provides evidence for the reversibility of liver fibrosis, even at 
the end-stage of fibrosis (cirrhosis) [2]. We believe that elucidating the mechanism of liver 
fibrosis can contribute to the development of therapies for reversing fibrosis or cirrhosis. 
However, liver fibrosis is a multicellular process that involves complex pathways, making it 
challenging to battle this disease. In this thesis, we used ex-vivo precision-cut liver slices to 
unravel the mechanism of gut-liver axis induced liver inflammation and liver fibrosis as well 
as evaluated two potential small molecules for their anti-fibrotic efficacy in different species.  
 
Liver fibrosis is a multicellular process 
Liver fibrosis is characterized by excessive extracellular matrix (ECM) accumulation due to 
the imbalance in the synthesis and degradation during chronic injury: upregulation of collagen 
synthesis and reduced degradation (downregulation of matrix metalloproteinase (MMPs) and 
increase of tissue inhibitor of matrix metalloproteinase (TIMPs)) [3]. When the liver injury is 
persistent, fibrosis may progress to cirrhosis, which is characterized by bridging fibrosis 
between portal veins, disrupted liver structure and even limiting or loss of vital liver function 
[4]. Activated myofibroblasts are considered to be the main player for ECM deposition [5]. 
Activated myofibroblast can derive from quiescent hepatic stellate cells (HSCs), bone marrow 
derived cells, portal fibroblast or epithelial-to-mesenchymal transition (EMT) [5]. Among 
these, HSCs activation is widely accepted as the key driver of liver fibrosis and a promising 
target cell for medicines to reverse fibrosis [6]. Toxins (e.g. carbon tetrachloride), viruses 
(hepatitis virus B, C), pathogen associate molecular patterns (PAMPs) (e.g. lipopolysaccharide 
(LPS), microbial nucleic acids and peptidoglycan) and oxidative stress or reactive oxygen 
species (ROS) can stimulate various pathways discussed in the next section that activate HSCs. 
In addition, macrophages in the liver, resident Kupffer cells and circulating monocytes 
developed from bone marrow cells, are instrumental in the liver fibrosis development by 
producing cytokines such as interleukin-6 (IL-6) and transforming growth factor-b (TGF-b) to 
activate HSCs [7]. Hepatocytes can sense the cytokines secreted by the macrophages, 
producing TGF-b and ROS to activate HSCs, which in return secrete TGF-b, IL-6 and TNF-a 
to stimulate hepatocytes to go into apoptosis or necrosis [8]. Taken together, liver fibrosis is a 
complex multicellular physiological process with intracellular communication to accomplish 
wound healing, however, an imbalance in this process will lead to a pathological state. The 
multicellular phenomena in liver fibrosis are shown in Figure 1. 









Figure 1: Simplified illustration of multicellular involvement in liver fibrosis  
HSCs (hepatic stellate cells; a-SMA (a-smooth muscle actin); TGF (transforming growth 
factor); IL (interleukin); TNF (tumor necrosis factor); ROS (reactive oxygen species); KC 
(Kupffer cells); HBV (hepatitis B virus); HCV (hepatitis C virus); PAMPs (pathogen 
associated molecular patterns); TIMPs (tissue inhibitors of metalloproteinases); MMPs (matrix 
metalloproteinases); HCC (hepatocellular carcinoma).  
  
Models used in liver fibrosis research 
Mechanism of fibrosis and antifibrotic drug efficacy are mostly studied in in vivo animal 
models and in vitro in primary cells and cell lines. In table 1 some of the classical models as 
well as novel developing models in liver fibrosis are listed. In vivo animal models for fibrosis 
commonly used in research include: alcohol-induced liver disease; carbon tetrachloride (CCl4) 
induced liver fibrosis; diet induced non-alcoholic fatty liver model; common bile duct ligation 
model and genetically modified fibrosis models [9].  Although in vivo animal models represent 
the best physiology model of a living animal, the limitations are: it takes a long time to develop 
(high cost, low throughput); inter-lab variability; risk of non-relevant results that do not or 
partially reflect the pathophysiology of human liver fibrosis and raises ethical concern for the 
animal welfare.  
 
In addition, the mechanism of fibrosis and the effect of potential anti-fibrotic drugs are also 
studied in in vitro models. HSCs can be studied using primary isolated cells or immortalized 
cell lines (e.g. mouse NIH 3T3, human LX-2) obtained from animal or human tissue [9]. 
Primary isolated cells are superior in representing the HSCs in vivo compared to cell lines, yet 
they are much harder to culture or manipulate in vitro and have only a limited life span [10]. 
In contrast, cell lines are normally easy to keep in long-term culture and can be manipulated 


































To mimic the multicellular aspect of fibrosis, co-cultures of the various cell types involved 
represent another model that is used in fibrosis research. Liver cells can be co-cultured to obtain 
the cell-cell interactions important during progression of fibrosis. Incubating or 3D culturing 
of hepatocytes with HSCs, Kupffer cells, sinusoidal endothelial cells and a mixture of non-
parenchymal cells is possible [12-14].  However, due to the different cellular sources and 
protocols the validation and reproducibility of these co-culturing systems are a concern [14, 
15]. Another possible 3D culture is represented by the hepatic organoids, which are 3D mini 
livers that can be obtained from actively dividing stem cells (Lgr5+) derived from damaged 
mouse liver [16]. In addition, the same group also developed organoids from adult bile duct-
derived bipotent progenitor cells, which could differentiate into in vitro and in vivo functional 
hepatocytes that could engraft into damaged mouse liver [17]. This system provides a 
promising model for screening drugs for efficacy or toxicity or transplantation of patient 
derived organoids to a damaged human liver [18, 19]. However, the relevance of this system 
to the human organ needs to be further explored and validated, since only 33-50% of the cells 
in the organoid differentiate into functional hepatocytes [20]. In addition, the organoids do not 
contain HSCs and other liver cells, making them less suitable for fibrosis research. The Liver-
on a chip is a 3D micro-physiological cell culture system on a microchip that aims to contain 
in vivo tissue components, mimic the functions, and maintain biochemical signals and the 
microenvironment [21-23]. Although it is a promising model to replace animal testing, and can 
be used to study multi-organ interactions or even personalized drug testing, careful validation 
of the protocols and cellular sources and functional characterization needs to be carried out 
before it can be widely applied [23]. In addition, inter laboratory variances exist, as there are 
no standard “chips” available [23].  
 
Compared to all discussed in vitro systems, the multicellular character of precision-cut liver 
slices (PCLS) seem to be more relevant to the in vivo situation as they are maintaining the 
cellular architecture and interactions in their original context. Moreover, human PCLS 
overcome translation between animal species and men and this makes it an appealing model 
for investigating the mechanism of fibrosis, anti-fibrotic drug efficacy or toxicity in a setting 
closer to man.  
 
Even though none of the above-mentioned models are perfect for representing the complex 
human physiology or pathology, they could provide valuable evidence to elucidate the 
mechanism of fibrosis. 
 
  








Table 1: Representative in vitro and in vivo models of liver fibrosis (modified from [9]) 
 Models Advantages Disadvantages 
In vivo    
Chemical induced Alcoholic Clinically relevant Low throughput 
 Carbon tetrachloride (CCl4) High reproducibility; 









acid defined diet 
Mimics human non-
alcoholic fatty liver 
disease or  
Inter lab variances due 
to differently 
standardized diet 
Low throughput  
 steatohepatitis  
   






associated protein 2 (Mdr2) 
knock-out 
Close to human chronic 
biliary injury 
Partly resembling the 
human pathophysiology  
In vitro    
Primary cells Primary HSCs Relatively good 
representation to HSCs in 
vivo 
Hard to culture & 
manipulate 
Limited life span 
Limited human material 
supply 
Cell lines LX-2 Easy to culture & 
manipulate with genetic 
tools 
Poor correlation with 
HSCs in in vivo 
Co-cultures Hepatocytes with HSCs, 
Kupffer cells or sinusoidal 
endothelial cells 
Presence of cell-cell 
interaction 
Validation and 
reproducibility of the 
system is uncertain 
Liver-on a chip Liver cells with or without 
cells from other organs 
Maintaining in vivo 
microenvironment 
Real time monitoring of 
culture system and 
metabolism 
Multi-organ interaction 
Protocols and platform 
varies between labs 
 
Hepatic organoids Stem cell derived hepatocytes Use of adult cell from 
patients, no genetic 
manipulation needed 
No presence of non-
parenchymal cells  
Relevance of human 




All resident cells the liver  Cell-cell interaction 
Standard protocol 
Physiologically relevant 
Limited life span 






Gut-liver axis and liver fibrosis 
Gut microbiota, considered as “the new virtual metabolic organ”, got rapid and global scientific 
interest because of its undeniable effect on the host physiology and during disease progression 
[24]. In liver diseases, also the quantity and quality of gut-microbiota changes (dysbiosis) [25]. 
Especially in liver fibrosis the gut permeability increases during disease progression, this will 
lead to increase of the pathogen-associated molecular proteins (PAMPs), the components of 
the gut microbiota, reaching the liver via the portal circulation [26]. This interaction between 
the liver and the gut is the so-called gut-liver axis. In alcoholic liver diseases, specifically in 
actively drinking patients with cirrhosis or severe alcoholic hepatitis patients, serum levels of 
LPS, a component of the Gram-negative bacteria, is dramatically increased, which may lead to 
liver injury through gut-liver axis [27]. Not only in alcoholic but also in the non-alcoholic 
steatohepatitis, the inflammation induced by the PAMPs is an important link between the initial 
metabolic stress, death of hepatocytes and fibrosis [25]. Toll like receptors (TLRs), which are 
responsible for sensing PAMPs, are one family of pattern recognition receptors in the innate 
immunity [28]. Most studies that studied TLRs and PAMPs and their effect on liver disease 
progression are described in Table 2. After activation of TLRs by PAMPs, various cytokines 
are produced by macrophages. Including IL-6, which promotes survival and proliferation of 
HSCs, TNF-a responsible for survival of HSCs and IL-1b, which activates HSCs [29-31]. 
Although inhibiting the inflammatory response is necessary to control the liver fibrosis 
progression, targeting of an individual cytokine might not be enough to inhibit fibrosis due to 
the complexity of the inflammatory reaction in liver fibrosis. 
  
Up until now, this discussion has been focusing on the liver side of the gut-liver axis, however 
managing the dysbiosis in the gut may also be a promising way of improving liver fibrosis 
progression. Untargeted approaches like changing diet, using probiotics/antibiotics or faecal 
microbial transplantation are possible to manage the gut microbiota [27]. However, 
personalized, precision bio-engineered bacterial strains or drugs that target specific bacteria 
seem more promising to accurately modulate the gut microbiota [32]. 
 
Although the gut microbiota is considered to be a bad player in liver disease development, our 
finding in Chapter 2 showed a positive role of the gut microbiota of providing a certain level 
of reduced sensitivity to LPS. Similar to our observation, the detrimental effect of the absence 
of the gut microbiota on liver pathology has been described: germ free (GF) mice are more 
responsive to chemical- or alcohol-induced liver injury and biliary tract injury [33-35]. 
Collectively, when using the GF rodents to study liver fibrosis or gut-liver axis, the 
hypersensitivity of them to a certain stimulus must be considered.  
  
The gut-liver axis related liver fibrosis is mainly studied in animal models as abovementioned.  
In Chapter 3, we investigated the effect of gut-liver axis derived LPS on human PCLS. During 
the different stages of liver disease, the LPS derived from the gut-liver axis may play different 
roles as shown in Chapter 3. At the initial state, LPS are promoting both inflammation and 
fibrosis, initiating the whole spectrum of the liver’s wound healing process; at the end-stage 
liver disease, LPS can only promote an elevated inflammatory response but will not lead to 
further progression of fibrosis. The enhanced inflammation might be due to a lower level of 








anti-inflammatory factor present (such as interleukin 1 receptor antagonist, IL-1Ra) compared 
to the situation in the healthy liver; in addition, the cirrhotic liver shows more regeneration-
related processes (represented by among others vascular endothelial growth factor (VEGF) and 
granulocyte-colony stimulating factor (G-CSF)) instead of further progression into fibrosis, 
unlike what was found for the healthy livers when encountering LPS. Furthermore, LPS 
upregulated a series of cytokines in the cirrhotic PCLS, and some of these cytokines have a 
role in cancer progression [36-40]. Thus, LPS might play a role in the progression from 
cirrhosis to hepatocellular carcinoma (HCC). It remains to be studied whether the above-
mentioned effect is also true for other PAMPs. 
 
Results from Chapter 2 and Chapter 3 from specific pathogen-free mouse and healthy human 
PCLS indicate that interleukin-1b (IL-1b) and IL-6 gene expression patterns were similar in 
mouse and human PCLS treated with LPS; the cytokine expression of IL-1b was similar at 24h 
with LPS, but not at 48h, where human IL-1b cytokine was still upregulated by LPS while this 
was not the case in murine PCLS. Tumor necrosis factor-a (TNF-a) gene expression was not 
upregulated at 24h in human PCLS by LPS, but it was enhanced in mouse PCLS at the same 
time point. However, the protein expressions of TNF-a were similar in mouse and human 
PCLS: upregulated at 24h and back to control level at 48h with LPS treatment. Our previous 
study on both rat and human PCLS showed that LPS induced TNF-a mRNA at 5h but not 24h, 
while the cytokine was upregulated at 24h by LPS [41].  These results suggest that there are 
time differences in the gene and protein expression of cytokines in the liver between rodent 
and human. 
 
Table 2: Representative toll-like receptors (TLRs) that are involved in liver fibrosis 
Receptor Ligands 
TLR-4 Lipopolysaccharide, low-molecular weight hyaluronic acid, heparin sulfate, 
saturated fatty acid, fibrinogen, fibronectin, heat shock proteins 60 and 70, high 
mobility group box-1, degraded matrix [42] 
TLR-9 Unmethylated CpG DNA found in bacteria or mammalian self DNA [43] 







Multiple pathways involved in liver fibrosis 
TGF-b signaling pathway is the well-accepted master regulator of liver fibrosis [45]. All the 
identified three isoforms (TGF-b1-3) have been reported to be involved in fibrosis, among 
which TGF-b1 is the most prominent one in liver fibrosis [46-48]. The latent TGF-b complex, 
which is inactive, can be cleaved by proteases (e.g. MMP2&9) to release the active TGF-b; 
only this active TGF-b binds to TGF-b receptor 2 (TbR2) as a homodimer, recruits and 
activates TbR1 to activate the downstream signaling pathway [49]. This TGF-b canonical 
signaling pathway will lead to phosphorylation of SMAD2&3 that in turn binds to SMAD4, 
which is then translocated to the nucleus to initiate transcription of specific genes that are 
responsible for activating myofibroblasts and ECM deposition [45]. In an alternative non-
canonical signaling pathway, TGF-b receptors activate, among others, mitogen-activated 
protein kinases (MAPK), phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (AKT) and 
Ras and Rho-like small GTPases [45]. In this thesis, we characterized the effect of blockade of 
TbR1 (Chapter 4) and TbR1/2 (Chapter 5) on liver fibrosis in order to shed more light on the 
involvement of TGF-b signalling in the mechanism of liver fibrosis and to elucidate species 
differences in this. Galunisertib, studied in Chapter 4 in human and rat PCLS, is a TbR1 
inhibitor that is aimed for treating hepatocellular carcinoma, and it is still in Phase 2 study, 
which is estimated to complete before the 1st May 2019. In vivo experiments in CCl4-treated 
mice showed that galunisertib exhibited an antifibrotic effect: less a-SMA positive cells, 
reduced fibrotic area and hydroxyproline content; but did not reduce gene expression of TIMP1 
[50]. Consistent with this observation, our results showed that galunisertib can reduce TGF-b 
signaling in human PCLS, reducing expression of various collagens and the enzymes involved 
in collagen maturation and fibril formation. On the other hand, not like in the CCl4 mouse 
model, gene expression of TIMP1 was downregulated by galunisertib in human PCLS, 
indicating a different effect of galunisertib on the collagen degradation enzymes in the two 
species. Moreover, according to our observation, the spontaneous onset of fibrosis in healthy 
and cirrhotic PCLS of the rat shares at least one common pathway that is due to TGF-b 
activation. While galunisertib as well as LY2109761 exhibited excellent antifibrotic efficacy, 
LY2109761 had an additional inhibitory effect on another pathway, e.g. bone morphogenetic 
protein (BMP) signaling pathway whose role in the fibrosis development is still controversial 
(either promoting or inhibiting) [51]. In Chapter 5, the overall effect of LY2109761 was anti-
fibrotic. This data suggests that either BMP signalling is pro-fibrotic or that inhibiting its anti-
fibrotic action does not result in increased fibrosis. Even though a broader inhibitory effect 
could lead to better antifibrotic properties, it might also increase the risk of additional toxicity.  
 
Activation of the TGF-b signaling pathway enhances ROS production in various liver cells 
[52], amplifying the liver inflammation and fibrosis. On the other hand, ROS transforms latent 
TGF-b into the active form to initiate the downstream signaling [53]. Thus, scavenging or 
balancing ROS derived oxidative stress is a challenging yet a potential substantial approach to 
combat fibrosis, as discussed extensively in Chapter 6. Future experiments with ROS-
inducing and inhibiting compounds in human PCLS could shed more light on the importance 
of ROS in fibrosis and the potential of anti-oxidants in fibrosis therapy. 
 








PCLS in fibrosis research 
PCLS have been used by us (this thesis and [41, 54-61]) and others [62-64] in fibrosis research, 
and the results show that the pathways involved in fibrosis are active in this model. An 
important motivation to use PCLS model is to reduce discomfort in animals by inducing 
inflammation by LPS in PCLS (Chapter 2) thereby avoiding the detrimental effects of LPS in 
vivo. Furthermore, by investigating the effect of LPS in human cirrhotic livers, no diseased 
animal models with high discomfort had to be used and human specific data were obtained 
(Chapter 4). Reduction in the number of animals and refinement were also accomplished by 
preparing and culturing liver slices from one animal and studying different conditions in one 
liver, while in an in vivo model only one condition can be studied per animal (Chapter 2 and 
4). The anti-fibrotic effect of galunisertib in vivo [50] was successfully mimicked in human 
and rat liver slices (Chapter 4). In addition, we showed that there are time differences in the 
gene and protein expression of cytokines by treating PCLS with LPS in the rodent and human 
liver (Chapter 2 and 3). Utilizing human PCLS can contribute to the translation from animal 
results to man (Chapter 3, 4 and 5), however more studies are necessary, when in the end anti-
fibrotic drugs are available, to confirm to what extent PCLS represent the in vivo situation in 
fibrosis research. Limitations of the PCLS model are the relative short life span of the slices 
and the absence of blood-derived immune cells in the PCLS. Extending the life span of human 
PCLS to 5 days has been achieved by choosing an enriched medium [65] and future research 
will show if this life span can be further extended. In addition, it might be interesting to culture 
the slices in the presence of blood-derived immune cells. Currently, we are trying to genetically 
modulate the precision-cut lung slices on gene and protein levels using siRNA [66], yet the 
application of this silencing technique in liver slices remains a challenge. Moreover, the scarce 






Liver fibrosis is a complex process not only involving various cells, but also multiple pathways: 
at least innate immune signaling (as discussed above), proliferative and fibrogenic pathways 
(among others TGF-b) are involved [6]. In addition, reactive oxygen species (ROS) produced 
by TLRs stimulated macrophages and damaged hepatocytes induce paracrine signals (for 
instance ROS and TGF-b) to activate HSCs [67] (Figure 1). Thus, targeting one cell type or 
signaling pathway may not be adequate for fibrosis treatment, multi-target strategy might 
provide more powerful impact on combatting liver fibrosis. The studies described in this thesis 
add to the conviction that human and animal PCLS could be a promising model to study the 
mechanism of fibrosis and exploring antifibrotic agents, and species-difference therein. 
Moreover, they contribute to the reduction and refinement of the use of experimental animals.  
 
Collectively, modulating the gut microbiota, inhibiting TGF-b signaling pathway and 
balancing the oxidative stress in the liver would provide promising strategies to treat fibrosis. 
However, the multi-organ, multicellular and multi-signaling pathway complexity and species 
differences make it challenging for the researchers to translate the knowledge of basic research 
into the clinic. By utilizing appropriate models to study the mechanism of fibrosis and to 
evaluate the drug efficacy of antifibrotic agents would assist the translational process from 
bench to bed-side. 
 
  










1. Nanthakumar, C.B., et al., Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat 
Rev Drug Discov, 2015. 14(10): p. 693-720. 
2. Jung, Y.K. and H.J. Yim, Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern 
Med, 2017. 32(2): p. 213-228. 
3. Pellicoro, A., et al., Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat 
Rev Immunol, 2014. 14(3): p. 181-94. 
4. Xu, R., Z. Zhang, and F.S. Wang, Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol 
Immunol, 2012. 9(4): p. 296-301. 
5. Iwaisako, K., D.A. Brenner, and T. Kisseleva, What's new in liver fibrosis? The origin of myofibroblasts 
in liver fibrosis. J Gastroenterol Hepatol, 2012. 27 Suppl 2: p. 65-8. 
6. Tsuchida, T. and S.L. Friedman, Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol 
Hepatol, 2017. 14(7): p. 397-411. 
7. Kazankov, K., et al., The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitis. Nat Rev Gastroenterol Hepatol, 2018. 
8. Tu, T., et al., Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis? J 
Gastroenterol Hepatol, 2015. 30(12): p. 1696-704. 
9. Yanguas, S.C., et al., Experimental models of liver fibrosis. Arch Toxicol, 2016. 90(5): p. 1025-1048. 
10. Weiskirchen, R. and A.M. Gressner, Isolation and culture of hepatic stellate cells. Methods Mol Med, 
2005. 117: p. 99-113. 
11. Herrmann, J., A.M. Gressner, and R. Weiskirchen, Immortal hepatic stellate cell lines: useful tools to 
study hepatic stellate cell biology and function? J Cell Mol Med, 2007. 11(4): p. 704-22. 
12. Giraudi, P.J., et al., The importance of the interaction between hepatocyte and hepatic stellate cells in 
fibrogenesis induced by fatty accumulation. Exp Mol Pathol, 2015. 98(1): p. 85-92. 
13. Rafal P. Witek, K.B.A., Manda A. Edwards, Adam M. Farmer, Kimberly M. Freeman, Erica Deibert, 
Tania Bembridge, Jonathan P. Jackson, Cornelia Smith, Jasminder Sahi, Stephen S. Ferguson, Mark J. 
Powers, Co-culture of Hepatocytes and Kupffer Cells as a Model for Liver Inflammation. 2010. 
14. Zeilinger, K., et al., Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro 
drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific 
functions. Altern Lab Anim, 2002. 30(5): p. 525-38. 
15. Zeilinger, K., et al., Cell sources for in vitro human liver cell culture models. Exp Biol Med (Maywood), 
2016. 241(15): p. 1684-98. 
16. Huch, M., et al., In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. 
Nature, 2013. 494(7436): p. 247-50. 
17. Huch, M., et al., Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell, 
2015. 160(1-2): p. 299-312. 
18. Fatehullah, A., S.H. Tan, and N. Barker, Organoids as an in vitro model of human development and 
disease. Nat Cell Biol, 2016. 18(3): p. 246-54. 
19. Au, S.H., et al., Hepatic organoids for microfluidic drug screening. Lab Chip, 2014. 14(17): p. 3290-9. 
20. Huch, M., S.F. Boj, and H. Clevers, Lgr5(+) liver stem cells, hepatic organoids and regenerative medicine. 
Regen Med, 2013. 8(4): p. 385-7. 
21. Andersen, M.E. and D. Krewski, Toxicity testing in the 21st century: bringing the vision to life. Toxicol 
Sci, 2009. 107(2): p. 324-30. 
22. Huh, D., G.A. Hamilton, and D.E. Ingber, From 3D cell culture to organs-on-chips. Trends Cell Biol, 
2011. 21(12): p. 745-54. 
23. Khazali, A.S., A.M. Clark, and A. Wells, A Pathway to Personalizing Therapy for Metastases Using 
Liver-on-a-Chip Platforms. Stem Cell Rev, 2017. 13(3): p. 364-380. 
24. Kataoka, K., The intestinal microbiota and its role in human health and disease. J Med Invest, 2016. 
63(1-2): p. 27-37. 
25. Friedman, S.L., et al., Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018. 
24(7): p. 908-922. 
26. Schnabl, B. and D.A. Brenner, Interactions between the intestinal microbiome and liver diseases. 
Gastroenterology, 2014. 146(6): p. 1513-24. 
27. Bajaj, J.S., Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2019. 
28. Amarante-Mendes, G.P., et al., Pattern Recognition Receptors and the Host Cell Death Molecular 
Machinery. Front Immunol, 2018. 9: p. 2379. 
29. Kong, X., et al., Cytokines and STATs in Liver Fibrosis. Front Physiol, 2012. 3: p. 69. 
30. Yang, Y.M. and E. Seki, TNFalpha in liver fibrosis. Curr Pathobiol Rep, 2015. 3(4): p. 253-261. 
31. Szabo, G. and J. Petrasek, Inflammasome activation and function in liver disease. Nat Rev Gastroenterol 
Chapter 7 
 166 
Hepatol, 2015. 12(7): p. 387-400. 
32. Sarin, S.K., A. Pande, and B. Schnabl, Microbiome as a therapeutic target in alcohol-related liver disease. 
J Hepatol, 2019. 70(2): p. 260-272. 
33. Chen, P., et al., Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. Alcohol Clin Exp 
Res, 2015. 39(12): p. 2313-23. 
34. Mazagova, M., et al., Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. 
FASEB J, 2015. 29(3): p. 1043-55. 
35. Tabibian, J.H., et al., Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine 
model of primary sclerosing cholangitis. Hepatology, 2016. 63(1): p. 185-96. 
36. Elsegood, C.L., et al., Immune checkpoint inhibition: prospects for prevention and therapy of 
hepatocellular carcinoma. Clin Transl Immunology, 2017. 6(11): p. e161. 
37. Xiong, G., et al., Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis 
by regulating collagen deposition. BMC Cancer, 2014. 14: p. 1. 
38. Chen, X., et al., Gene expression patterns in human liver cancers. Mol Biol Cell, 2002. 13(6): p. 1929-
39. 
39. Ip, Y.C., et al., Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular 
carcinoma. World J Gastroenterol, 2005. 11(40): p. 6269-76. 
40. Alpizar-Alpizar, W., et al., Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated 
Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma. J Histochem Cytochem, 
2016. 64(8): p. 483-94. 
41. Elferink, M.G., et al., LPS-induced downregulation of MRP2 and BSEP in human liver is due to a 
posttranscriptional process. Am J Physiol Gastrointest Liver Physiol, 2004. 287(5): p. G1008-16. 
42. Guo, J. and S.L. Friedman, Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. 
Fibrogenesis Tissue Repair, 2010. 3: p. 21. 
43. Garcia-Martinez, I., et al., Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by 
activation of TLR9. J Clin Invest, 2016. 126(3): p. 859-64. 
44. Rivera, C.A., et al., Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC 
Gastroenterol, 2010. 10: p. 52. 
45. Fabregat, I., et al., TGF-beta signalling and liver disease. FEBS J, 2016. 283(12): p. 2219-32. 
46. Huang, T., S.L. Schor, and A.P. Hinck, Biological activity differences between TGF-beta1 and TGF-
beta3 correlate with differences in the rigidity and arrangement of their component monomers. 
Biochemistry, 2014. 53(36): p. 5737-49. 
47. Dropmann, A., et al., TGF-beta1 and TGF-beta2 abundance in liver diseases of mice and men. Oncotarget, 
2016. 7(15): p. 19499-518. 
48. Xu, F., et al., TGF-beta/SMAD Pathway and Its Regulation in Hepatic Fibrosis. J Histochem Cytochem, 
2016. 64(3): p. 157-67. 
49. Meng, X.M., D.J. Nikolic-Paterson, and H.Y. Lan, TGF-beta: the master regulator of fibrosis. Nat Rev 
Nephrol, 2016. 12(6): p. 325-38. 
50. Atsutaka Masuda, et al., Promotion of Liver Regeneration/Anti-Fibrotic Effects of TGF-β Receptor 
Kinase Inhibitor Galunisertib in CCl4-Treated Mice and the Possibility for Clinical Application. 
Hepatology, 2018. 68(S1): p. 184-1353. 
51. Herrera, B., A. Addante, and A. Sanchez, BMP Signalling at the Crossroad of Liver Fibrosis and 
Regeneration. Int J Mol Sci, 2017. 19(1). 
52. Liu, R.M. and L.P. Desai, Reciprocal regulation of TGF-beta and reactive oxygen species: A perverse 
cycle for fibrosis. Redox Biol, 2015. 6: p. 565-77. 
53. Krstic, J., et al., Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in 
Tumorigenesis and Cancer Progression. Oxid Med Cell Longev, 2015. 2015: p. 654594. 
54. de Graaf, I.A., et al., Preparation and incubation of precision-cut liver and intestinal slices for application 
in drug metabolism and toxicity studies. Nat Protoc, 2010. 5(9): p. 1540-51. 
55. Olinga, P., et al., Rat liver slices as a tool to study LPS-induced inflammatory response in the liver. J 
Hepatol, 2001. 35(2): p. 187-94. 
56. Olinga, P. and D. Schuppan, Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol, 2013. 
58(6): p. 1252-3. 
57. van de Bovenkamp, M., et al., Precision-cut liver slices as a new model to study toxicity-induced hepatic 
stellate cell activation in a physiologic milieu. Toxicol Sci, 2005. 85(1): p. 632-8. 
58. van de Bovenkamp, M., et al., Precision-cut fibrotic rat liver slices as a new model to test the effects of 
anti-fibrotic drugs in vitro. J Hepatol, 2006. 45(5): p. 696-703. 
59. Vatakuti, S., et al., Validation of precision-cut liver slices to study drug-induced cholestasis: a 
transcriptomics approach. Arch Toxicol, 2017. 91(3): p. 1401-1412. 
60. Westra, I.M., et al., Human precision-cut liver slices as a model to test antifibrotic drugs in the early 








onset of liver fibrosis. Toxicol In Vitro, 2016. 35: p. 77-85. 
61. Westra, I.M., et al., The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One, 
2014. 9(4): p. e95462. 
62. Palma, E., E.J. Doornebal, and S. Chokshi, Precision-cut liver slices: a versatile tool to advance liver 
research. Hepatol Int, 2019. 13(1): p. 51-57. 
63. Lev-Cohain, N., et al., Real-time ALT and LDH activities determined in viable precision-cut mouse liver 
slices using hyperpolarized [1-(13) C]pyruvate-Implications for studies on biopsied liver tissues. NMR 
Biomed, 2019. 32(2): p. e4043. 
64. Wu, X., et al., Precision-cut human liver slice cultures as an immunological platform. J Immunol 
Methods, 2018. 455: p. 71-79. 
65. Starokozhko, V., et al., Maintenance of drug metabolism and transport functions in human precision-cut 
liver slices during prolonged incubation for 5 days. Arch Toxicol, 2017. 91(5): p. 2079-2092. 
66. Ruigrok, M.J.R., et al., siRNA-mediated protein knockdown in precision-cut lung slices. Eur J Pharm 
Biopharm, 2018. 133: p. 339-348. 
67. Puche, J.E., Y. Saiman, and S.L. Friedman, Hepatic stellate cells and liver fibrosis. Compr Physiol, 
2013. 3(4): p. 1473-92
  168 
